All patients have been recruited to a prospective clinical study on Episurf Medical’s Episealer Talus implant.
The study will follow 20 patients who received an Episealer Talus implant as treatment for osteochondral defects in their ankle joint. Episealer Talus is Episurf Medical’s CE Marked implant technology, intended for the treatment of ankle lesions.
“Our technology for ankle lesions is getting more and more attention internationally and we are very pleased that this study is fully recruited. The study started under difficult conditions during the pandemic, but the recruitment has now been concluded in a very efficient way. We are looking forward to the results, and it is, as always, an honour to work with the prestigious Rizzoli Orthopaedic Institute in Bologna,” says Pål Ryfors, CEO Episurf Medical.
All patients have been recruited to a prospective clinical study on Episurf Medical's Episealer Talus implant.
The study will follow 20 patients who received an Episealer Talus implant as treatment for osteochondral defects in their ankle joint. Episealer Talus is Episurf Medical’s CE Marked implant technology, intended for the treatment of...
All patients have been recruited to a prospective clinical study on Episurf Medical’s Episealer Talus implant.
The study will follow 20 patients who received an Episealer Talus implant as treatment for osteochondral defects in their ankle joint. Episealer Talus is Episurf Medical’s CE Marked implant technology, intended for the treatment of ankle lesions.
“Our technology for ankle lesions is getting more and more attention internationally and we are very pleased that this study is fully recruited. The study started under difficult conditions during the pandemic, but the recruitment has now been concluded in a very efficient way. We are looking forward to the results, and it is, as always, an honour to work with the prestigious Rizzoli Orthopaedic Institute in Bologna,” says Pål Ryfors, CEO Episurf Medical.
Copy to clipboard 
